Related Experiment Video

Updated: Jul 7, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Anti-Canine Mammary Carcinoma Effects of mPP-Based Nano-Micelles Encapsulating DPIA

Yuhong Chen1, Han Wang1, Zhenyu Wang1

  • 1Natural Medicine Research Center, Department of Pharmacy, Sichuan Agricultural University, Chengdu, China.

Veterinary and Comparative Oncology
|July 6, 2026
PubMed

Insights

Researchers developed nano-micelles (DPIA@mPP) to improve the efficacy of the antitumor agent DPIA for triple-negative breast cancer (TNBC). This novel formulation enhanced drug delivery and significantly boosted tumor inhibition in a canine model, offering a promising new strategy.

Area of Science:

  • Oncology
  • Nanotechnology
  • Veterinary Medicine

Background:

  • Triple-negative breast cancer (TNBC) poses a significant therapeutic challenge.
  • Canine mammary carcinoma serves as a relevant spontaneous model for TNBC research.
  • Developing effective drug delivery systems is crucial for improving TNBC treatment outcomes.

Purpose of the Study:

  • To encapsulate the antitumor agent DPIA into mPEG-PCL (mPP) nano-micelles to enhance its in vivo therapeutic efficacy.
  • To evaluate the physicochemical properties, in vitro cytotoxicity, and in vivo antitumor activity of DPIA@mPP.
  • To investigate the potential mechanisms of action of DPIA@mPP in canine mammary carcinoma cells.

Main Methods:

  • Synthesis of mPEG-PCL (mPP) nano-micelles and encapsulation of DPIA.
  • Characterization of DPIA@mPP, including drug loading and encapsulation efficiency.
  • In vitro cytotoxicity assays using canine mammary carcinoma cells (CMT-7364).
  • In vivo studies in a canine mammary carcinoma model to assess tumor inhibition and toxicity.
  • Preliminary mechanistic studies involving apoptosis and signaling pathway analysis (PI3K/AKT).

Main Results:

  • DPIA@mPP exhibited uniform dispersion and spheroid-like architecture with a drug loading of 4.31% and encapsulation efficiency of 13.10%.
  • DPIA@mPP demonstrated comparable in vitro cytotoxicity to free DPIA and enhanced cellular uptake.
  • In vivo studies showed increased tumor inhibition from 30.31% to 48.55% with DPIA@mPP compared to free DPIA, alongside reduced toxicity.
  • DPIA@mPP displayed superior in vivo antitumor efficacy and a favorable safety profile.

Conclusions:

  • Nano-micelle encapsulation of DPIA (DPIA@mPP) significantly enhances its in vivo antitumor efficacy and safety for treating canine mammary carcinoma, a model for TNBC.
  • DPIA@mPP shows potential for promoting apoptosis via PI3K/AKT pathway inhibition, offering new insights for TNBC therapeutic strategies.
  • This study highlights the potential of nano-micelle drug delivery systems in improving cancer treatment outcomes.
Keywords:
2‐phenylindole derivativesanti‐ canine mammary carcinoma effectsmPEG‐PCLnano‐micellestriple‐negative breast cancer

More Related Videos

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

Related Concept Videos